Issues of cost-effectiveness in the use of antithrombotic therapy for ischemic heart disease.
Publication
, Journal Article
Califf, RM; Mark, DB
Published in: Am Heart J
November 1997
Duke Scholars
Published In
Am Heart J
ISSN
0002-8703
Publication Date
November 1997
Volume
134
Issue
5 Pt 2
Start / End Page
S88 / S96
Location
United States
Related Subject Headings
- Myocardial Ischemia
- Humans
- Fibrinolytic Agents
- Drug Costs
- Cost-Benefit Analysis
- Cardiovascular System & Hematology
- 3201 Cardiovascular medicine and haematology
- 1117 Public Health and Health Services
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Califf, R. M., & Mark, D. B. (1997). Issues of cost-effectiveness in the use of antithrombotic therapy for ischemic heart disease. Am Heart J, 134(5 Pt 2), S88–S96.
Califf, R. M., and D. B. Mark. “Issues of cost-effectiveness in the use of antithrombotic therapy for ischemic heart disease.” Am Heart J 134, no. 5 Pt 2 (November 1997): S88–96.
Califf RM, Mark DB. Issues of cost-effectiveness in the use of antithrombotic therapy for ischemic heart disease. Am Heart J. 1997 Nov;134(5 Pt 2):S88–96.
Califf, R. M., and D. B. Mark. “Issues of cost-effectiveness in the use of antithrombotic therapy for ischemic heart disease.” Am Heart J, vol. 134, no. 5 Pt 2, Nov. 1997, pp. S88–96.
Califf RM, Mark DB. Issues of cost-effectiveness in the use of antithrombotic therapy for ischemic heart disease. Am Heart J. 1997 Nov;134(5 Pt 2):S88–S96.
Published In
Am Heart J
ISSN
0002-8703
Publication Date
November 1997
Volume
134
Issue
5 Pt 2
Start / End Page
S88 / S96
Location
United States
Related Subject Headings
- Myocardial Ischemia
- Humans
- Fibrinolytic Agents
- Drug Costs
- Cost-Benefit Analysis
- Cardiovascular System & Hematology
- 3201 Cardiovascular medicine and haematology
- 1117 Public Health and Health Services
- 1102 Cardiorespiratory Medicine and Haematology